BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

786 related articles for article (PubMed ID: 29891109)

  • 1. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
    Vos S; van Diest PJ; Moelans CB
    Crit Rev Oncol Hematol; 2018 Jul; 127():29-41. PubMed ID: 29891109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
    Vos S; Moelans CB; van Diest PJ
    Breast Cancer Res; 2017 May; 19(1):64. PubMed ID: 28569220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation not a frequent "second hit" in tumors with germline BRCA mutations.
    Dworkin AM; Spearman AD; Tseng SY; Sweet K; Toland AE
    Fam Cancer; 2009; 8(4):339-46. PubMed ID: 19340607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
    Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
    Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas.
    Vos S; Elias SG; van der Groep P; Smolders YH; van Gils CH; van Diest PJ
    Am J Surg Pathol; 2018 Sep; 42(9):1262-1272. PubMed ID: 29979200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
    Maxwell KN; Wubbenhorst B; Wenz BM; De Sloover D; Pluta J; Emery L; Barrett A; Kraya AA; Anastopoulos IN; Yu S; Jiang Y; Chen H; Zhang NR; Hackman N; D'Andrea K; Daber R; Morrissette JJD; Mitra N; Feldman M; Domchek SM; Nathanson KL
    Nat Commun; 2017 Aug; 8(1):319. PubMed ID: 28831036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
    Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
    Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
    Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
    Singer CF; Tan YY; Muhr D; Rappaport C; Gschwantler-Kaulich D; Grimm C; Polterauer S; Pfeiler G; Berger A; Tea MM
    Cancer Med; 2019 Apr; 8(4):1875-1881. PubMed ID: 30821131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
    Riahi A; Chabouni-Bouhamed H; Kharrat M
    Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No association between BRCA mutations and sex ratio in offspring of Pakistani BRCA mutation carriers.
    Rashid MU; Torres D; Zaidi A; Rasheed F; Sultan F; Shakoori AR; Amin A; Hamann U
    Breast Cancer Res Treat; 2008 Jan; 107(1):155-6. PubMed ID: 18043900
    [No Abstract]   [Full Text] [Related]  

  • 14. Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
    Riahi A; Ghourabi ME; Fourati A; Chaabouni-Bouhamed H
    Breast Cancer; 2017 Mar; 24(2):238-244. PubMed ID: 27025497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endometrial Cancer in Germline BRCA Mutation Carriers: A Systematic Review and Meta-analysis.
    Matanes E; Volodarsky-Perel A; Eisenberg N; Rottenstreich M; Yasmeen A; Mitric C; Lau S; Salvador S; Gotlieb WH; Kogan L
    J Minim Invasive Gynecol; 2021 May; 28(5):947-956. PubMed ID: 33249269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in Ovarian and Other Cancers Risks by Population and
    Sekine M; Nishino K; Enomoto T
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
    Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
    Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.